BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 25465343)

  • 21. Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice.
    Satkunam N; Wei X; Biagi JJ; Nanji S; Booth CM
    J Natl Compr Canc Netw; 2016 Dec; 14(12):1548-1554. PubMed ID: 27956539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
    Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
    PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.
    Hsiao FY; Mullins CD; Onukwugha E; Pandya N; Hanna N
    J Am Geriatr Soc; 2011 Sep; 59(9):1717-23. PubMed ID: 21831168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
    Park YS; Ji J; Zalcberg JR; El-Serafi M; Buzaid A; Ghosn M
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):334-42. PubMed ID: 26471890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer.
    Bos AC; van Erning FN; van Gestel YR; Creemers GJ; Punt CJ; van Oijen MG; Lemmens VE
    Eur J Cancer; 2015 Nov; 51(17):2553-61. PubMed ID: 26360411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.
    Smoragiewicz M; Javaheri KR; Yin Y; Gill S
    J Gastrointest Cancer; 2014 Dec; 45(4):460-5. PubMed ID: 25012517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
    Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
    Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer.
    Sun Z; Adam MA; Kim J; Nussbaum DP; Benrashid E; Mantyh CR; Migaly J
    Dis Colon Rectum; 2016 Feb; 59(2):87-93. PubMed ID: 26734965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer.
    Loree JM; Mulder KE; Ghosh S; Spratlin JL
    Clin Colorectal Cancer; 2014 Sep; 13(3):172-7. PubMed ID: 24630275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
    Kim HR; Min BS; Kim JS; Shin SJ; Ahn JB; Rho JK; Kim NK; Rha SY
    Oncology; 2011; 81(3-4):175-83. PubMed ID: 22057187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant chemotherapy for stage III colon cancer: does timing matter?
    Czaykowski PM; Gill S; Kennecke HF; Gordon VL; Turner D
    Dis Colon Rectum; 2011 Sep; 54(9):1082-9. PubMed ID: 21825887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer.
    Hershman D; Hall MJ; Wang X; Jacobson JS; McBride R; Grann VR; Neugut AI
    Cancer; 2006 Dec; 107(11):2581-8. PubMed ID: 17078055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
    Hassan AS; Naicker M; Yusof KH; Wan Ishak WZ
    Asian Pac J Cancer Prev; 2015; 16(6):2237-43. PubMed ID: 25824744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
    Cheung WY; Shi Q; O'Connell M; Cassidy J; Blanke CD; Kerr DJ; Meyers J; Van Cutsem E; Alberts SR; Yothers G; Sargent DJ;
    Clin Colorectal Cancer; 2013 Sep; 12(3):179-87. PubMed ID: 23810482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new look at the International Duration Evaluation of Adjuvant therapy (IDEA) classification-Defining novel predictive and prognostic markers in stage III colon cancer.
    Margalit O; Mamtani R; Yang YX; Reiss KA; Golan T; Halpern N; Aderka D; Giantonio B; Shacham-Shmueli E; Boursi B
    Eur J Cancer; 2018 Jun; 96():105-110. PubMed ID: 29698932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
    Zaanan A; Cuilliere-Dartigues P; Guilloux A; Parc Y; Louvet C; de Gramont A; Tiret E; Dumont S; Gayet B; Validire P; Fléjou JF; Duval A; Praz F
    Ann Oncol; 2010 Apr; 21(4):772-780. PubMed ID: 19833818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit of Oxaliplatin in Stage III Colon Cancer According to IDEA Risk Groups: Findings from the ACCENT Database of 4934 Patients.
    Margalit O; Boursi B; Rakez M; Thierry A; Yothers G; Wolmark N; Haller DG; Schmoll HJ; Shi Q; Shacham-Shmueli E; de Gramont A
    Clin Colorectal Cancer; 2021 Jun; 20(2):130-136. PubMed ID: 33775561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
    Zhang Y; Ma J; Zhang S; Deng G; Wu X; He J; Pei H; Shen H; Zeng S
    Int J Colorectal Dis; 2015 Sep; 30(9):1173-83. PubMed ID: 26054387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.